VOSEVI
MARKETED BY: Gilead SciencesINDICATION: The FDA approved Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) to treat chronic hepatitis C virus infection genotypes 1-6 in patients without cirrhosis or with mild cirrhosis.DOSAGE FORM: Tablets: 400-mg sofosbuvir, 100- mg velpatasvir, and 100-mg voxilaprevirFOR MORE INFORMATION: gilead.comIDHIFA
MARKETED BY: CelgeneINDICATION: The FDA has approved Idhifa (enasidenib) to treat adult patients with relapsed or refractory acute myeloid leukemia who have an isocitrate dehydrogenase- 2 gene mutation.DOSAGE FORM: Tablets: 50 mg or 100 mgFOR MORE INFORMATION: Celgene.comTREMFYA
MARKETED BY: Janssen BiotechINDICATION: The FDA has approved Tremfya (guselkumab) to treat adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.DOSAGE FORM: Injection: 100 mg/mLFOR MORE INFORMATION: janssen.comBLINCYTO
MARKETED BY: AmgenINDICATION: The FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) to include overall survival data from the phase 3 TOWER study, converting Blincytoâ€™s accelerated approval to a full approval. The approval expands the indication of Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.DOSAGE FORM: Injection: 35 mcgFOR MORE INFORMATION: amgen.com
